HIF1A and colorectal carcinoma: This leads to a reduction in CD31-/PAS+ double-stained VM channels in vivo, indicating that Evo inhibits VM in colorectal cancer (CRC) by targeting the HIF-1α/VE-cadherin/VEGF/MMPs signaling axis (Zeng et al., 2021).